Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Why i am not accumulating
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(150)
•••
Comment by Goaweighon Feb 19, 2021 1:47pm
99 Views
Post# 32611311

RE:RE:RE:RE:RE:Why i am not accumulating

RE:RE:RE:RE:RE:Why i am not accumulatingI've been thinking about Off label applications, of course we need to get 346 approved first but if it completely buffers any negative effects of the nsaids part of the drug then it becomes an H2S delivery system and not an nsaids delivery system although the nsaids part may have benefits too, depending on the use. For IBD for instance the nsaids, even if effectively buffered may still have a negative effect on the gut, but maybe not, while the H2S may have a profoud positive effect. Same with Covid, and maybe the nsaids portion may be effective against brain swelling in the case of Alzhiemers, if indeed that is one of the problems, getting through the blood/brain barrier may be the problem. 
Of course a Co. can't promote on the basis of it's drug having Off label potential but it would be fascinating if we knew what the possibilities were. 


MrMugsy wrote: Goaweigh ... you also asked about COVID.  I didn't responded to that one.

For COVID, you need to refer to the BioPUB conference call when Dan was specificially asked about a COVID trial.  Dan said he wan't able to discuss at this time.

Cheers !


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities